$OGN

Organon Canada, a subsidiary of Organon & Co. (OGN), announced approval of NDUVRA 1% cream for atopic dermatitis in patients aged 2+. The steroid-free treatment was previously approved for plaque psoriasis. Atopic dermatitis affects up to 20% of children and 3% of adults globally. OGN shares closed at $13.73, up 0.07% on Friday.

Organon (OGN) announced FDA acceptance of a supplemental New Drug Application for MIUDELLA, seeking to extend its use from 3 to 6 years. The FDA decision is expected in Q2 2027. MIUDELLA is currently approved for 3-year use and is anticipated to launch commercially in late 2026. Clinical trials showed 99% contraceptive effectiveness. Organon licensed MIUDELLA from Sebela Women's Health in June 2026.

Origin Enterprises plc transferred 15,349 treasury shares to satisfy share options under its Savings Related Share Option Scheme (UK). The number of treasury shares decreased from 12,050,357 to 12,035,008, with 107,706,523 ordinary shares in issue. The company is listed on Euronext Growth Dublin and the AIM market of the London Stock Exchange.

Organon (NYSE: OGN) said its MIUDELLA copper IUD REMS program is open for enrollment via www.miudellarems.com. The REMS requires individual provider and separate healthcare setting certifications to support dispensing and insertion, aiming to reduce complications from improper insertion. MIUDELLA is indicated for up to three years of pregnancy prevention.

Drinane Juliana Papa (Head of Mfg & Supply) sold 14,761 shares of Organon & Co. (OGN) at $13.57 ($0.20M total) on 2026-08-05.

Organon & Co. (OGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001821825 0001821825 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

OTC Markets Group said Orogen Royalties Inc (TSX-V: OGN, OTCQX: OGNNF) qualified to trade on OTCQX Best Market, upgrading from OTCQB. It will trade on OTCQX under symbol OGNNF, with U.S. investors able to access disclosures and Level 2 quotes on OTCMarkets.com. Orogen focuses on precious and base metal royalties in North America.

Organon & Co. (OGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001821825 0001821825 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Hanmi Pharmaceutical has announced a partnership with Organon to export three of its combination therapies for cardiovascular and respiratory conditions to Malaysia and the Philippines. This agreement strengthens Hanmi's presence in the rapidly growing Southeast Asian pharmaceutical market, with Organon handling marketing, distribution, and sales. Both companies aim to expand treatment options and improve access to medicines in the region.

Organon (NYSE:OGN) reported a miss on Wall Street's revenue and earnings expectations for Q1 CY2026, with sales declining 3.5% year-on-year to $1.46 billion and adjusted EPS coming in 16.8% below consensus at $0.71. The company has shown a struggle with consistent revenue growth and decreasing profitability over the past several years. Analysts anticipate revenue to remain flat and full-year EPS to grow marginally in the next 12 months, highlighting ongoing challenges for the pharmaceutical firm.